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1  | INTRODUC TION
Inherited	 bleeding,	 thrombotic,	 and	 platelet	 disorders	 (BTPD)	 are	 a	
heterogeneous	 set	of	diseases.	The	most	 common	 inherited	bleed-
ing	 disorders	 are	 von	 Willebrand	 disease	 (VWD)	 and	 hemophilia,	
although	all	other	BTPDs	are	globally	very	rare,	with	mostly	an	un-
known	prevalence.	Over	the	past	five	decades,	the	genetic	basis	of	
some	of	these	disorders	has	been	identified.	Most	of	the	genes	har-
boring	 variants	 responsible	 for	BTPD	have	been	 identified	 through	
linkage	 studies	 across	 informative	 pedigrees	 or	 using	 candidate	
gene	 Sanger	 sequencing	 following	 thorough	 clinical	 and	 laboratory	
workup.1	However,	over	the	past	decade,	high-	throughput	sequencing	
has	become	the	primary	means	of	identifying	disease-	causing	genetic	
variants.2	Different	diagnostic	gene	panel	tests	for	BTPD	have	been	
developed	 using	 targeted	 or	 exome	 sequencing.1,3–9	 Interestingly,	
when	comparing	 the	gene	 content	of	 these	different	 genetic	panel	
tests,	 significant	 differences	were	 observed.	 A	 first	 level	 of	 differ-
ence	was	created	by	the	choice	of	genes	tested	for	BTPD.	These	in-
cluded	established	genes,	known	for	decades	to	play	a	role	in	many	
families	with	BTPD	(e.g.,	F8, F9, VWF, PROS1, PROC, ITGA2B, ITGB3,	
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amongst	many	others),	genes	with	limited	evidence	from	publications	
of	single	pedigrees,	and,	 finally,	genes	 identified	 through	 functional	
studies	 and/or	knockout	mice	but	without	 a	 known	defined	 role	 in	
human	pathology.	The	first	group	of	genes	are	the	diagnostic-	grade	
(hereafter	named	TIER1)	genes,	whereas	 the	others	are	 referred	 to	
as	TIER2	and	TIER3	genes,	respectively.	A	second	level	of	difference	
is	that	some	panels	contain	genes	that	are	related	to	bleeding	but	are	
not	considered	classical	coagulation	or	platelet	regulatory	genes,	such	
as	 those	 for	 hereditary	 hemorrhagic	 telangiectasia	 (ENG, SMAD4, 
ACVRL11),	Ehlers	Danlos	syndrome	(e.g.,	COL1A1, COL3A1, COL5A1, 
COL5A2, CHST14),	 Gaucher	 syndrome	 (GBA),	 or	 Noonan	 syndrome	
(e.g.,	PTPN11).	 These	 genes	 are	 TIER1	 genes	 for	 disorders	 that	 are	
often	 associated	 with	 primary	 phenotypes	 such	 as	 arteriovenous	
malformations,	 joint	 hypermobility,	 skin	 hyperextensibility,	 tissue	
fragility,	and	complex	syndromic	features	that	result	in	an	increased	
bleeding	tendency.	These	primary	symptoms	are	typically	recognized	
by	a	clinical	expert,	but	systematic	screening	of	these	genes	in	a	pa-
tient	population	with	unexplained	bleeding	symptoms	has	not	been	
performed;	 therefore,	 inclusion	of	an	“extended”	TIER1	BTPD	gene	
list	can	be	considered.
Providing	a	molecular	diagnosis	 to	BTPD	patients	 is	highly	desir-
able	because	it	aids	prognostication,	may	alter	therapy,	and	provides	
important	 information	 for	 counseling.	Making	 incorrect	 assumptions	
about	variants	could	be	harmful,	however.10	There	are	potential	pitfalls	
when	interpreting	the	role	of	genetic	variants	in	genes	related	to	BTPD.	
The	published	literature,	disease	(Online	Mendelian	Inheritance	in	Man	
[OMIM];	http://omim.org)	and	variant	databases	(ClinVar;	https	://www.
ncbi.nlm.nih.gov/clinv	ar/	and	the	Human	Gene	Mutation	Database)	are	
incomplete	and	littered	with	misinformation	about	gene-	disease	asso-
ciations	and	erroneous	interpretation	of	the	pathogenicity	of	variants.	
It	is	essential	when	assigning	pathogenicity	that	rigorous	standards	are	
applied	to	variants	in	fully	evidenced	TIER1	genes.	The	first	step	in	pro-
viding	diagnostic-	grade	genetic	reports	is	gene	curation.	Gene	curation	
is	 intended	to	help	physicians	and	clinical	geneticists	decide	a	gene's	
role	in	a	disease	and	provide	information	on	the	mode	of	inheritance	
and	 mutational	 disease	 mechanism.	 The	 process	 of	 selecting	 TIER1	
core	genes	for	BTPD	was	taken	up	by	the	Scientific	and	Standardization	
Committee	(SSC)	for	Genetics	in	Thrombosis	and	Haemostasis	(GinTH).	
The	current	study	explains	the	different	aspects	related	to	this	curation	
process	and	presents	an	up-	to-	date	TIER1	gene-	disease	list	for	BTPD,	
useful	for	clinical	genetic	testing,	the	design	of	gene	panel	tests,	or	for	
filtering	whole	exome	or	whole	genome	sequencing	data.
2  | DESCRIPTION OF THE GENE AND 
TR ANSCRIPT CUR ATION PROCESS
2.1 | Historical background and gene curation process
We	have	assembled	a	list	of	91	TIER1	genes	that	are	germline	mutated	
(except	one,	PIGA)	and	are	causally	 implicated	 in	BTPD	(Table	1;	 for	
the	full	version,	see	Table	S1).	The	gene	curation	project	was	initiated	
by	the	SSC-	GinTH	in	2014	when	63	genes	and	transcripts	were	sug-
gested	by	experts	of	the	clinical	and	scientific	community	 (Table	S2)	
to	be	used	 for	 genetic	 testing	of	BTPDs.	New	genes	 and	modes	of	
inheritance	have	been	curated	and	discussed	at	four	subsequent	SSC-	
GinTH	meetings	before	designation	to	TIER1	status.	These	new	genes	
required	a	status	of	strong	evidence	as	specified	later	in	more	detail.	
Genes	were	grouped	in	three	main	categories:	21	genes	mostly	related	
to	 coagulation	 deficiencies	 implicated	 in	 bleeding,	 9	 genes	 known	
to	be	associated	with	 thrombosis,	and	61	genes	 involved	 in	defects	
related	 to	platelet	 function	and	 their	 formation	by	blood	stem	cells.	
Four	genes	could	have	been	assigned	to	multiple	categories;	F2,	F5,	
and THBD	to	bleeding	and	thrombosis,	and	VWF	to	bleeding,	but	also	
VWD	type	2B,	which	is	considered	a	platelet	disorder.	Here	the	differ-
ence	in	clinical	phenotype	is	caused	by	the	variant	type	(inactivation	
vs	activating)	or	location	within	the	gene.	This	information	is	encoded	
in	Table	S1	as	“Mutational	mechanism	for	the	disease.”	The	predicted	
effect	of	a	gene	variant	often	indicates	the	impact	of	a	disease;	there-
fore,	we	have	curated	the	categories	of	variants	that	occur	 in	BTPD	
TIER1	 genes	 that	 cause	 disease.	Most	BTPDs	 are	 caused	by	 inacti-
vating	missense	or	loss-	of-	function	(LoF)	variants	that	are	distributed	
throughout	 the	gene,	whereas	others	 are	exclusively	 caused	by	LoF	
variants	 (e.g.,	PIGA, BLOC1S3, BLOC1S6, DTNBP1, FYB1).	 In	contrast,	
some	BTPDs	are	the	result	of	activating	missense	or	LoF	variants	that	
mostly	 occur	 in	 specific	 protein	 domains	 (e.g.,	 THBD, DIAPH1, SRC, 
F5, F2).	 Finally,	 noncoding	variants	 have	 also	 been	 shown	 to	 cause	
BTPDs	(e.g.,	3′UTR	variant	in	F2,	5′UTR	variants	in	ANKRD26,	variants	
in	the	noncoding	gene	RNU4ATAC).	Genes	with	multiple	disorders	as-
sociated	with	different	clinical	or	laboratory	phenotypes	(e.g.,	GP1BA,	
GP1BB,	ITGA2B,	ITGB3)	have	been	represented	as	independent	rows	
in	Table	S1,	and	multiple	modes	of	inheritance	(e.g.,	VWF, FLI1, GFI1B, 
PROC)	are	encoded	within	the	“Inheritance”	column.
To	 curate	each	gene-	disease	pair,	 three	 layers	of	 evidence	were	
collated	that	provide	support	for	disease	association,	mode	of	inher-
itance	 and	 disease-	causing	 “mutational	 mechanism.”	 The	 first	 level	
of	 evidence	was	 provided	 by	 reviewing	 the	 primary	 literature	 using	
PubMed	searches,	OMIM,	and	gene-	specific	databases	(e.g.,	Medical	
College	of	Wisconsin-	maintained	database	for	Glanzmann	thrombas-
thenia	and	European	Association	for	Hemophilia	and	Allied	Disorders-	
maintained	databases	for	F7, F8, F9,	and	VWF)	to	evaluate	the	genetic	
confidence	 for	 a	 gene	 being	 disease-	causing	 (“Level	 1	 evidence”	 in	
Table	S1).	For	each	gene-	disease	pair,	genotype-	phenotype	cosegre-
gation	data,	the	mode	of	inheritance	and	the	disease-	causing	mutation	
mechanism	were	reviewed	in	at	least	three	independent	families.	For	
six	genes	(AP3D1, BLOC1S3, FYB1, HOXA11, NBEA, and SRC),	only	two	
unrelated	families,	whereas	for	PLAU,	a	single	but	very	large	pedigree	
with	28	affected	patients	and	a	significant	 linkage	association	signal	
(logarithm	of	odds	score	+11)	for	the	PLAU	locus,	were	reported.11	The	
second	 layer	 of	 evidence	was	 provided	 by	 knowledge	 from	 specific	
hemostasis,	platelet,	or	molecular	assays	or	phenotypes	that	support	
gene-	disease	associations	(“Level	2	evidence”	in	Table	S1).	A	third	layer	
of	evidence	consisted	of	the	existence	of	a	mouse	model	affecting	the	
ortholog	of	the	human	gene	and	presenting	with	the	same	phenotype	
as	 the	 associated	 human	 disease.	 This	 information	was	 taken	 from	
the	Mouse	 Genome	 Informatics	 (www.infor	matics.jax.org)	 database	
or	 a	 PubMed	 reference	 (“Level	 3	 evidence”	 in	Table	 S1).	 Twenty	 of	
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the	genes	had	a	mouse	model	that	did	not	mimic	the	human	disease,	
whereas	for	five	genes,	no	model	has	been	developed.
In	 summary,	 evidence-	based	 curation	 resulted	 in	 a	 total	 of	 91	
genes	 that	 reached	 a	 TIER1	 status	 (Table	 1).	 These	 were	 gene-	
disease	association	identified	in	at	 least	three	genetically	 indepen-
dent	 families	 with	 supportive	 genotype-	phenotype	 cosegregation	
data	or	with	robust	support	from	functional	studies	and/or	a	mouse	
phenocopy	 matching	 the	 human	 disease	 where	 less	 than	 three	
families	 are	 known	 in	 combination	 with	 linkage	 analysis	 data	 for	
large	pedigrees.	The	list	 is	versioned	and	will	be	reassessed	by	the	
SSC-	GinTH	at	 the	 yearly	 International	 Society	on	Thrombosis	 and	
Haemostasis	meeting.
2.2 | Transcript curation process
When	reporting	likely	pathogenic	and	pathogenic	variants,	it	is	essen-
tial	to	report	on	a	fixed,	evidenced-	based	transcript.	For	each	TIER1	
gene,	 the	 curated	 transcript	was	 selected,	 in	 collaboration	with	 the	
Locus	 Reference	 Genomic	 project	 (LRG;	 http://www.lrg-	sequence.
org/),12	 based	 on	 recommendations	 by	members	 of	 the	 SSC-	GinTH	
community,	 previously	 reported	 causal	 variants	 in	 Human	 Gene	
Mutation	Database	 and	ClinVar,	 transcript	 and	 protein	 lengths,	 and	
considering	 RNA-	sequencing	 expression	 data	 in	 blood	 cells,	 other	
relevant	 tissues,	 and	 cap	 analysis	 gene	 expression	data	 for	 defining	
the	most	common	transcription	start	site	(Table	1	and	Table	S1).	For	
some	genes,	more	than	one	transcript	was	included	in	the	LRG	record.	
In	 general,	 these	 transcripts	 include	 additional	 and	 well-	supported	
protein-	coding	exons	not	present	in	the	transcript	highlighted	in	the	
tables.	The	TIER1	BTPD	gene	and	transcript	list	is	accessible	at	https	:// 
www.isth.org/page/GinTh_GeneL	ists.
3  | CONCLUSION
Although	 specific	 guidelines	 for	 variant	 interpretation	 in	 TIER1	
genes	 have	 been	 published	 by	 the	 American	 College	 of	 Medical	
Genetics	and	Genomics,13	guidelines	for	assessing	the	association	of	
a	specific	gene	with	a	specific	disease	are	still	nascent.	The	Clinical	
Genome	Resource,	ClinGen,	is	coordinating	expert	analysis	of	gene-	
disease	 associations	 using	 a	 comprehensive	 and	 publicly	 available	
criteria	 using	 evidence	 including	 the	 number	 of	 reported	 patients	
with	variants	 in	 the	gene	and	supporting	experimental	data	 for	all	
rare	diseases.14	A	ClinGen	clinical	domain	working	group	for	throm-
bosis	 and	 hemostasis	 has	 been	 initiated	 (https	://www.clini	calge	
nome.org/worki	ng-group	s/clini	cal-domai	n/hemos	tasis-throm	bosis-
clini	cal-domain-worki	ng-group/	)	in	2017.	Curating	the	links	between	
genes	and	disease	is	a	complex	and	demanding	task.	ClinGen	gene	
curation	efforts	for	different	disease	working	groups	(e.g.,	epilepsy,	
RASopathies)	 have	 applied	 detailed	 scoring	 system	 using	 asso-
ciation's	strength	classified	as	definitive,	strong,	moderate,	 limited,	
disputed,	 or	 no	 evidence	 to	 systematically	 evaluate	 gene-	disease	
relationships.15,16	Because	of	the	urgent	need	in	diagnostic	genetic	
laboratories,	the	SSC-	GinTH	has	already	applied	a	simplified	scoring	
system	 to	 specify	 the	 definitive	 gene-	disease	 pairs	 relevant	 for	
BTPD.	Our	experience	highlights	the	importance	of	careful	literature	
curation	and	evaluation	by	experts	in	the	field.	Our	scoring	system	is	
simple	enough	to	be	quickly	implemented	while	updating	the	TIER1	
gene	database	with	the	latest	findings	and	it	can	specifically	guide	
diagnostic	 laboratories.	 Further,	 we	 find	 that	 review	 of	 previous	
cases	while	 updating	 clinical	 validity	 of	 gene-	disease	 relationships	
can	 contribute	 to	 increased	diagnostic	 rates	 resulting	 in	 improved	
patient	care.
When	 implementing	 the	 BTPD	 gene	 list	 for	 diagnostics,	 good	
practice	 suggests	 that	 gene	panels	 are	 applied,	 either	 through	 the	
testing	of	specific	genes	using	targeted	panels	or	through	the	appli-
cation	of	virtual	panels	 to	whole	genome	and	exome	data,	 limiting	
the	number	of	potentially	pathogenic	variants	to	those	in	genes	rel-
evant	to	a	patient's	condition,	and	reducing	the	possibility	of	 iden-
tifying	incidental	pathogenic	variants.	Incidental	findings	associated	
with	BTPD	can	include	the	identification	of	variants	known	to	be	as-
sociated	with	hemophilia	in	unaffected	female	carriers	and	variants	
associated	with	mild	to	moderate	thrombocytopenia	but	also	caus-
ing	an	increased	risk	of	malignancy	(RUNX1,	ANKRD26,	and	ETV6).	
Concerns	regarding	these	findings	have	recently	been	discussed	and	
solutions	 include	 the	 necessity	 of	 discussing	 these	 risks	 with	 pa-
tients	before	consenting	and	performing	a	genetic	test	or	that	virtual	
subpanels	of	genes	are	created	(with	or	without	genes	with	risk	for	
incidental	findings)	that	would	allow	a	patient	to	choose.17,18	Future	
discussion	must	center	on	the	consent	process	that	must	also	con-
sider	 the	 local	 laws	of	 the	country,	 the	 risks	of	discrimination,	 the	
policy	of	 the	genetic	 testing	 service,	 and	 the	age	of	 the	 individual	
being	tested.	Our	main	goal	was	to	deliver	a	curated	BTPD	disease-	
causing	gene	list	for	use	by	diagnostic	laboratories;	however,	as	ge-
netic	 testing	 becomes	 more	 common	 through	 biobanking	 studies	
and	direct-	to-	consumer	testing,	this	list	may	also	be	used	in	research	
studies	 and	 to	 aid	 appropriate	 feedback	 of	 genetic	 information	 to	
participants.
The	rapid	pace	of	gene	discovery	using	whole	exome	sequencing	
or	whole	 genome	 sequencing	 approaches	 also	 emphasizes	 a	 need	
for	data	 sharing.	Many	 recent	putative	discoveries	were	made	 for	
single	small	pedigrees,	sometimes	accompanied	by	limited	functional	
studies	and	no	mouse	model;	 therefore,	without	further	evidence,	
these	 genes	 are	 designated	 TIER2.	 These	 include	macrothrombo-
cytopenia	resulting	from	a	recessive	missense	variant	in	PRKACG,19 
macrothrombocytopenia	 from	dominant	 loss-	of-	function	variant	 in	
TPM4,20	 macrothrombocytopenia	 from	 a	 dominant	 missense	 vari-
ant in TRPM7,21	 a	 platelet	 function	 defect	 from	 recessive	 EPHB2 
variants,22	and	thrombocytopenia	from	a	recessive	PTPRJ	LoF	vari-
ants.23	Such	TIER2	genes	are	relevant	for	BPTD	diagnostics	but	still	
require	 confirmation	 studies	 in	 independent	 pedigrees	 and	 there-
fore,	the	SSC-	GinTH	encourages	the	publication	of	such	short	con-
firmation	reports.
In	conclusion,	recent	curation	efforts	by	membership	of	the	SSC-	
GinTH	now	provide	 a	well-	curated	 and	 evidence-	based	 catalog	of	
TIER1	gene-	disease	associations	that	can	be	used	for	diagnostic	ge-
netic	screening	of	BTPD	patients.
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